Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude sur la sécurité et l'efficacité de la crème au tapinarof à 1 % chez les participants âgés de 3 mois à moins de 24 mois atteints de dermatite atopique (Adoring)

6 novembre 2026 mis à jour par: Organon and Co

Étude de phase 3 randomisée, en double aveugle, contrôlée par véhicule (période 1) et en ouvert (période 2) pour étudier l'innocuité et l'efficacité de la crème de tapinarof à 1 % chez des participants pédiatriques âgés de 3 mois à < 24 mois atteints de dermatite atopique

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Type d'étude

Interventionnel

Inscription (Réel)

187

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alberta
      • Calgary, Alberta, Canada, T2J 7E1
        • Dermatology Research Institute
      • Red Deer, Alberta, Canada, T4P 1K4
        • CARe Clinic (Central Alberta Research Clinic)
    • British Columbia
      • Surrey, British Columbia, Canada, V3R 6A7
        • Dr. Chih-Ho Hong Medical Inc.
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3J 0S9
        • Manitoba Allergy Research Inc.
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 5R3
        • Maritime Dermatology
    • Ontario
      • Burlington, Ontario, Canada, L7L 6W6
        • Halton Pediatric Allergy
      • Hamilton, Ontario, Canada, L8S 1G5
        • Triple A Lab Inc.
      • Niagara Falls, Ontario, Canada, L2H 1C4
        • Allergy Research Canada Inc.
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4V 1R9
        • Dr. Rachel Asiniwasis Medical Professional Corporation
      • Saskatoon, Saskatchewan, Canada, S7K 2C1
        • Skinsense Medical Research
    • Alabama
      • Birmingham, Alabama, États-Unis, 35209
        • AllerVie Clinical Research
    • Arkansas
      • Bryant, Arkansas, États-Unis, 72022
        • Dermatology Trial Associates
    • California
      • Los Angeles, California, États-Unis, 90045
        • Dermatology Research Associates
      • Sacramento, California, États-Unis, 95815
        • Integrative Skin Science and Research
      • San Diego, California, États-Unis, 92123
        • Allergy and Asthma Medical Group and Research Center
      • Thousand Oaks, California, États-Unis, 91320
        • Clinical Trials Research Institute
    • Colorado
      • Castle Rock, Colorado, États-Unis, 80109
        • Clarity Dermatology
    • Florida
      • Boca Raton, Florida, États-Unis, 33486
        • Skin Care Research, LLC.
      • Jacksonville, Florida, États-Unis, 32256
        • APEX Clinical Trials
      • Wellington, Florida, États-Unis, 33449
        • TruDerm Research
    • Georgia
      • Cumming, Georgia, États-Unis, 30040
        • Cleaver Medical Group Dermatology, Inc
    • Idaho
      • Meridian, Idaho, États-Unis, 83646
        • Ada West Research
    • Illinois
      • Skokie, Illinois, États-Unis, 60077
        • Endeavor Health Clinical Trials Center
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46250
        • Dawes Fretzin Clinical Research Group, LLC
      • Plainfield, Indiana, États-Unis, 46168
        • The Indiana Clinical Trials Center, PC
    • Kentucky
      • Bowling Green, Kentucky, États-Unis, 42104
        • Equity Medical, LLC
    • Maryland
      • Rockville, Maryland, États-Unis, 20850
        • Lawrence J Green, MD LLC
    • Michigan
      • Auburn Hills, Michigan, États-Unis, 48326
        • Oakland Hills Dermatology
    • Minnesota
      • New Brighton, Minnesota, États-Unis, 55112
        • Minnesota Clinical Study Center
    • Mississippi
      • Ridgeland, Mississippi, États-Unis, 39157
        • SKY Integrative Medical Center
    • Missouri
      • Saint Joseph, Missouri, États-Unis, 64506
        • MediSearch Clinical Trials
    • Nevada
      • Reno, Nevada, États-Unis, 89509
        • Skin Cancer and Dermatology Institute
    • New York
      • Kew Gardens, New York, États-Unis, 11415
        • Forest Hills Dermatology Group
      • New York, New York, États-Unis, 10012
        • Bobby Buka MD, PC
      • The Bronx, New York, États-Unis, 10455
        • Equity Medical, LLC
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27516
        • The University of North Carolina Dermatology and Skin Cancer Center
    • Ohio
      • Fairborn, Ohio, États-Unis, 45324
        • Dermatologists of Central States, LLC
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73120
        • Allergy Asthma and Clinical Research Center
    • Oregon
      • Portland, Oregon, États-Unis, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, États-Unis, 97239
        • Oregon Health & Science University
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29425
        • Medical University of South Carolina
      • North Charleston, South Carolina, États-Unis, 29420
        • National Allergy and Asthma Research, LLC.
    • Texas
      • Bellaire, Texas, États-Unis, 77401
        • The University of Texas Health Science Center at Houston
      • Dallas, Texas, États-Unis, 75230
        • Dermatology Treatment and Research Center
      • Southlake, Texas, États-Unis, 76092
        • Stryde Research - Epiphany Dermatology
    • Washington
      • Spokane, Washington, États-Unis, 99202
        • Dermatology Specialists of Spokane

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

3 mois à 1 an (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
  • Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
  • Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
  • Legal guardian or primary caregiver is able and willing to adhere to protocol requirements

Exclusion Criteria:

  • Significant neurological disorder or history of seizure
  • Know clinically significant cardiac rhythm or cardiac disorder
  • History of sudden infant death in a sibling
  • Clinically significant chromosome abnormality
  • History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
  • Diseases that could cause pruritic and/or sleep disruption
  • Immunocompromised
  • Current chronic or acute infection requiring treatment
  • Use of prohibited medication(s) or procedure(s)
  • Use of prohibited medications by breastfeeding mother if breastfeeding participant

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Tapinarof cream

Tapinarof cream, 1%, applied topically once daily

Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.

Autres noms:
  • DMVT-505
  • OG-0505
  • GSK2894512A
  • GSK28994512
  • STI-1001
  • WBI-1001
Comparateur placebo: Vehicle cream

Vehicle cream is applied topically once daily for up to 8-weeks.

Applied topically once daily to lesions on participant's skin during the Double-Blind period.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Délai: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Délai: Baseline to the end of the Open-Label Period, up to 56 weeks.

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to the end of the Open-Label Period, up to 56 weeks.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Délai: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Délai: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Délai: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Délai: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Délai: Baseline to the end of the Open-Label Period, up to 56 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Délai: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Délai: Baseline to the end of the Open-Label Period, up to 56 weeks.

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Délai: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Délai: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Délai: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Délai: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Clinical Lead Late-Stage Clinical Development, Organon and Co

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

29 décembre 2025

Achèvement primaire (Estimé)

1 août 2027

Achèvement de l'étude (Estimé)

1 août 2027

Dates d'inscription aux études

Première soumission

21 novembre 2025

Première soumission répondant aux critères de contrôle qualité

2 décembre 2025

Première publication (Réel)

4 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

6 novembre 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner